The label expansion is based on findings from the pivotal phase 3 DELIVER trial in which dapagliflozin reduced the composite CV/HF endpoint in HF patients with
HFmrEF or HFpEF.
AACE 2023. Deaths among persons with diabetes in the US related to vascular complications increased from 2001 to 2020, primarily driven by renal complications.
The dual GIP/GLP-1 receptor agonist was associated with a nearly 15% reduction in body weight in adults with overweight/obesity and without type 2 diabetes.